

Swiss Radiopharmacy Day, Wednesday 11th of March 2026, FOPH

Schwarzenburgstrasse 157, CH-3003 Berne (Liebefeld/Köniz)

Abstracts Swiss Radiopharmacy Day 2026

PET4Pets: Leveraging Interspecies Oncology to Advance Precision Medicine

(Lars Frieder Gerchow, PET4pets PSI)

Targeted and precision medicine demand more specific diagnostic tools, yet current PET/CT imaging lags behind modern cancer therapies, while translation from preclinical models to humans remains a major bottleneck.

PET4Pets leverages naturally occurring cancers in dogs to accelerate innovation by integrating ETH Zurich's PET detector development, PSI's radiochemistry for novel tracers, and clinical veterinary expertise, building on successful proof-of-concept PET/CT studies.

By developing a dedicated PET scanner and optimized acquisition pipelines for veterinary oncology, the project establishes a new diagnostic standard for pets while creating a fast, clinically relevant pathway for translating imaging agents and technologies to human medicine.

Immuno-PET: From Radiochemistry to RadioFlow

(Cécile Philippe, "Experimental Nuclear Medicine" Medical University of Vienna)

Immuno-PET has emerged as a powerful tool to visualize immune biology in vivo. This talk highlights recent advances in Immuno-PET tracers, with a focus on small-molecule and metabolic probes such as [¹⁸F]FAC for imaging immune cell activity. In addition, the radioFlow technique is introduced as a novel approach enabling high-resolution tracking of radiotracer behavior at the cellular level and opening new perspectives for Immuno-PET tracer development.

Organising a Nuclear Medicine Ecosystem in Switzerland: Aligning Interdependent Actors to Accelerate Innovation and Patient Access

(Lukas Aebi, Geschäftsführer Nuklearforum Schweiz)

Nuclear medicine is a highly interconnected technology domain in which progress depends on many interdependent actors – from radionuclide production and radiopharmaceutical manufacturing to pharmaceutical research & development, logistics, hospitals, clinicians, regulators and patient organisations. Fragmentation along this value chain can delay innovation and limit reliable patient access. This presentation examines how such an ecosystem can be organised to ensure that scientific advances translate into scalable capacity and reliable patient access.

Keynote Lecture

Molecular imaging in Alzheimer's disease: from disease modeling to targeted treatments

(Valentina Garibotto, Head of Nuclear Medicine HUG)

The talk will highlight how molecular imaging is reshaping our understanding of Alzheimer's disease and related disorders and accelerating the development of targeted therapies. By visualizing key pathological processes—such as amyloid deposition, tau aggregation, and neurodegeneration—advanced imaging biomarkers allow researchers to model disease progression with greater precision. These tools improve early diagnosis, support patient stratification, and guide therapeutic interventions, ultimately paving the way for personalized and effective treatment strategies.

Positronium lifetime imaging: are we really just made of water?

(Lorenzo Mercolli, Inselspital)

In this talk, I will introduce the concept of positronium lifetime imaging and report initial results acquired on a commercial long axial field-of-view PET/CT scanner.

To date no other abstracts available.